Article No
155-98-624
Specifications
| NCBI Number | 12525 |
| Accession Number | P01731 |
| Application | ELISA, IP, WB |
| Article No | 155-98-624 |
| Country Availability | SE, FI, DK, NO, IS, EE, LV, LT, FO, GL |
| Clone | 53-6.7 |
| Clone Type | monoclonal |
| Concentration | 0.1 mg/ml |
| Conjugation | APC/Cy5.5 |
| Description | CD8a Antibody [53-6.7] (APC-Cy5.5) |
| Supplier | ProSci |
| Entrez Gene ID | 12525 |
| Format | Liquid |
| Gene Symbol | Cd8a |
| Immunogen | Spleen cells or thymocyte membranes |
| Isotype | IgG2a |
| Notes | In the mouse, CD8 exists in two forms – (i) a CD8 heterodimer composed of an alpha chain (CD8alpha) and a beta chain (CD8beta); and (ii) a homodimer of two alpha chains. The heterodimer is found on the surface of essentially all thymocytes and the “suppressor/cytotoxic” subpopulation of mature T lymphocytes. Subsets of intestinal intraepithelial lymphocytes express CD8alpha without CD8beta. It has been suggested that CD8+beta- T cells mature extrathymically, while development of the CD8alpha+beta+ population of T cells is thymus-dependent. CD8 acts as a coreceptor with MHC Class I-restricted T cell receptors in antigen recognition and positive selection of MHC class I-restricted CD8+ T cells. In vivo and in vitro treatment with the 53-6.7 monoclonal antibody effectively depletes CD8alpha+ cells. The 53-6.7 monoclonal antibody also blocks allogeneic help specific for class I MHC antigens and T cell responses to IL-2. |
| Alias Names | Ly-2, Lyt-2, Ly-35, Ly-B, T8 |
| Previous Article No | 155-98-624-0.1 |
| Product Type | Antibodies Primary |
| Protocol | CD8a Antibody [53-6.7] for use in flow cytometry assays. |
| Research area | Immunology |
| Shipping Information | BLUE ICE |
| Size | 0.1 mg |
| Source / Host | rat |
| Species Reactivity | mouse |
| Storage | 4°C |
| Substrate / Buffer | Supplied in PBS/NaN3 and a stabilizing agent |
| Technical Specifications | CD8a Antibody [53-6.7] for use in flow cytometry assays. |
| UniProt Number | P01731 |
| Product Page Updated | 2024-01-03T13:34:25.701Z |
